GAL-021

GAL-021
Clinical data
Routes of
administration		 Intravenous
Legal status
Legal status
Identifiers
PubChem (CID) 57340959
Chemical and physical data
Formula C11H22N6O
Molar mass 254.331 g/mol
3D model (Jmol) Interactive image

GAL-021 is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BKCa potassium channel,[1] although secondary mechanisms may also be involved.[2] It was developed by Galleon Pharmaceuticals, and is being tested in clinical trials for potential uses in post-operative care,[3] as well as more generally to counteract the respiratory depression which can be a side effect of opioid analgesic drugs.[4][5][6]

See also

References

  1. ↑ McLeod JF, Leempoels JM, Peng SX, Dax SL, Myers LJ, Golder FJ. GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. Br J Anaesth. 2014 Nov;113(5):875-83. doi: 10.1093/bja/aeu182 PMID 24989775
  2. ↑ Santhosh M Baby, Toshinori Hoshi, Sean Peng, Scott L Dax, Francis J Golder, D Euan MacIntyre and James C Mannion. Comparison of the respiratory effects of GAL-021 in BK α subunit knockout (Slo1–/ –) and wild-type mice. FASEB Journal. April 2012 26 (Meeting Abstract Supplement) 704.30
  3. ↑ Golder FJ, Hewitt MM, McLeod JF. Respiratory stimulant drugs in the post-operative setting. Respir Physiol Neurobiol. 2013 Nov 1;189(2):395-402. doi: 10.1016/j.resp.2013.06.010 PMID 23791825
  4. ↑ Santhosh M Baby, Ryan B Gruber, Veljko Puskovic, Sean Peng, Scott L Dax, Francis J Golder, D Euan MacIntyre and James C Mannion. GAL-021, a novel respiratory stimulant, attenuates opioid–induced respiratory depression without compromising analgesia. FASEB Journal. April 2012 26 (Meeting Abstract Supplement) 704.28
  5. ↑ van der Schier R, Roozekrans M, van Velzen M, Dahan A, Niesters M. Opioid-induced respiratory depression: reversal by non-opioid drugs. F1000Prime Rep. 2014 Sep 4;6:79. doi: 10.12703/P6-79. PMID 25343036
  6. ↑ Roozekrans M, van der Schrier R, Okkerse P, Hay J, McLeod JF, Dahan A. Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers. Anesthesiology. 2014 Sep;121(3):459-68. doi: 10.1097/ALN.0000000000000367 PMID 25222672


This article is issued from Wikipedia - version of the 6/18/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.